Abstract
Background: MCLA-129, a novel human, EGFR/c-MET bispecific antibody, demonstrates anti-tumor activities in EGFR and/or c-MET driven tumor models via multiple mechanisms, including inhibition of ligand binding, receptor co-degradation, antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. MCLA-129 is being investigated in patients (pts) with advanced solid tumors in an ongoing First in Human study (NCT04868877). EGFR and c-MET are frequently mutated or overexpressed in epithelial tumors, driving ligand-independent receptor activation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
